VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Treatment-Related Toxicity in Advanced MTC

Panelists: Ezra Cohen, MD, University of Chicago; Eric J. Sherman, MD, MSKCC; Steven I. Sherman, MD, MD Anderson; R. Michael Tuttle, MD, MSKCC
Published: Thursday, Sep 19, 2013
For High-Definition, Click
Unique side effects are associated with each drug approved to treat patients with metastatic medullary thyroid cancer (MTC). As antiangiogenic agents, both vandetanib and cabozantinib are associated with hypertension, diarrhea, intestinal perforations, and tracheal esophageal fistula, notes Steven I. Sherman, MD. These side effects should be managed closely, particularly since diarrhea is already associated with MTC.

There is a risk for QT interval prolongation for patients treated with vandetanib, points out Sherman. As a result, patients treated with this drug should be monitored closely by electrocardiogram. Additionally, vandetanib is associated with cutaneous side effects, mucositis, rash, and photosensitivity.

As a result of these toxicities, not all patients are candidates for treatment. For stable patients, active surveillance should be utilized, suggests R. Michael Tuttle, MD. However, for rapidly progressive disease, the benefits of aggressive treatment may outweigh the risks.

The final decision about whether to administer cabozantinib or vandetanib should include input from a multidisciplinary team and can be individualized based on the patient's preference, specifically in the case of borderline progressive and stable disease, notes Lori J. Wirth, MD. These drugs may be warranted, for patients with 2 cm metastatic lesions that grow by 25% of more over the course of a year, believes Sherman.



Slider Left
Slider Right
For High-Definition, Click
Unique side effects are associated with each drug approved to treat patients with metastatic medullary thyroid cancer (MTC). As antiangiogenic agents, both vandetanib and cabozantinib are associated with hypertension, diarrhea, intestinal perforations, and tracheal esophageal fistula, notes Steven I. Sherman, MD. These side effects should be managed closely, particularly since diarrhea is already associated with MTC.

There is a risk for QT interval prolongation for patients treated with vandetanib, points out Sherman. As a result, patients treated with this drug should be monitored closely by electrocardiogram. Additionally, vandetanib is associated with cutaneous side effects, mucositis, rash, and photosensitivity.

As a result of these toxicities, not all patients are candidates for treatment. For stable patients, active surveillance should be utilized, suggests R. Michael Tuttle, MD. However, for rapidly progressive disease, the benefits of aggressive treatment may outweigh the risks.

The final decision about whether to administer cabozantinib or vandetanib should include input from a multidisciplinary team and can be individualized based on the patient's preference, specifically in the case of borderline progressive and stable disease, notes Lori J. Wirth, MD. These drugs may be warranted, for patients with 2 cm metastatic lesions that grow by 25% of more over the course of a year, believes Sherman.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x